Einführung

The Court of Appeals for the Federal Circuit delivered a decisive affirmation on February 19, 2026, upholding Corcept Therapeutics’ patent infringement claims against generic drug giant Teva Pharmaceutical Industries, Ltd. in Case No. 24-1346. The appellate ruling, closing a litigation journey spanning 770 days, confirmed the validity and enforceability of four patents covering the concomitant administration of glucocorticoid receptor (GR) modulators with CYP3A inhibitors — the pharmacological backbone of Corcept’s branded mifepristone therapy, Korlym.

For pharmaceutical patent practitioners, this outcome reinforces a critical and increasingly contested frontier in drug patent litigation: method-of-treatment and drug-drug interaction patents as durable barriers against ANDA-based generic entry. The Federal Circuit’s affirmance signals that carefully drafted pharmaceutical combination therapy patents can survive appellate scrutiny, carrying profound implications for branded pharmaceutical companies defending exclusivity windows, generic manufacturers planning market entry, and R&D teams designing next-generation formulations.

Fallübersicht

Die Parteien

Streitige Patente

Four U.S. patents were central to this dispute, covering methods related to the **concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors** — addressing clinically significant drug-drug interactions that arise when mifepristone is co-administered with drugs metabolized through the CYP3A enzyme pathway. These patents represent layered protection across dosing adjustments, patient management protocols, and combination therapy methods.

• • US8921348B2 — Methods for concomitant administration of GR modulators and CYP3A inhibitors
• • US9829495B2 — Pharmaceutical compositions and methods of use thereof
• • US10195214B2 — Methods for treating conditions requiring GR antagonism
• • US10842800B2 — Methods of using glucocorticoid receptor modulators

Zeitplan des Rechtsstreits und Verfahrensgeschichte

The case was filed on January 11, 2024, at the Court of Appeals for the Federal Circuit, situated in the District of Columbia. The appeal-level filing indicates this matter arose from prior district court proceedings — the Federal Circuit review representing the culminating appellate stage of what was likely an underlying Hatch-Waxman ANDA litigation.

The case closed on February 19, 2026, after 770 days — a duration consistent with complex pharmaceutical patent appeals involving multiple patents and sophisticated pharmacological claim constructions. The Federal Circuit, which holds exclusive jurisdiction over patent appeals nationwide, is the definitive appellate authority for all U.S. patent infringement disputes, making its affirmance in this case particularly authoritative.

The 770-day span reflects the depth of briefing and analysis required when multiple patents covering layered drug interaction methods are contested simultaneously — a timeline not atypical for high-stakes Hatch-Waxman appellate battles.

Das Urteil und die rechtliche Analyse

Ergebnis

The Federal Circuit entered judgment with a clear directive: AFFIRMED. The court upheld the lower tribunal’s findings in Corcept’s favor on the infringement action, sustaining the enforceability of all four patents against Teva’s challenges. No specific damages amount was disclosed in the available case data, consistent with Hatch-Waxman cases where the primary remedy sought is injunctive relief blocking generic market entry rather than retrospective monetary damages.

Urteilsursachenanalyse

The infringement action arose from Teva’s ANDA filing — a statutory act of infringement under 35 U.S.C. § 271(e)(2). The patents at issue cover method-of-treatment claims directed to managing patients on mifepristone when co-administered with strong CYP3A inhibitors, requiring dose adjustments and clinical monitoring. These types of claims are particularly valuable because generic drug labels that incorporate identical prescribing guidance can constitute induced infringement under 35 U.S.C. § 271(b).

The Federal Circuit’s affirmance suggests the lower court’s claim construction and infringement analysis withstood appellate scrutiny. In pharmaceutical method patents, the label-based infringement theory — where a generic’s FDA-mandated prescribing information effectively instructs the infringing method — has been a contested but increasingly recognized pathway. The survival of this theory through Federal Circuit review strengthens Corcept’s enforcement posture significantly.

Teva’s defense team at Sterne Kessler likely advanced invalidity arguments (obviousness, written description, or enablement challenges) alongside non-infringement positions — standard defense architecture in ANDA litigation. The affirmance indicates these challenges were insufficient to disturb the lower court’s findings across all four patents.

Rechtliche Bedeutung

This decision carries meaningful precedential weight in pharmaceutical patent litigation for several reasons:

1. Multi-patent portfolio affirmance: Sustaining four related patents simultaneously reinforces the viability of layered patent family strategies around drug administration methods.
2. CYP3A inhibitor interaction patents: The Federal Circuit’s endorsement of drug-drug interaction method claims as infringed by generic ANDA labels sets a notable marker for similar pharmaceutical combinations.
3. Label-based induced infringement: The outcome likely reflects continued Federal Circuit acceptance of prescribing information as sufficient basis for inducement claims under Eli Lilly v. Teva Parenteral progeny.

Auswirkungen auf die Branche und den Wettbewerb

The Federal Circuit’s affirmance delivers a significant commercial victory for Corcept Therapeutics, effectively extending Korlym’s market exclusivity against Teva’s generic entry. Given Korlym’s position as the only FDA-approved drug for Cushing’s syndrome-related hyperglycemia, the stakes were considerable — annual revenues from the product have historically exceeded $300 million.

For Teva and the broader generic pharmaceutical industry, the ruling underscores the mounting challenge of navigating brand pharmaceutical companies’ increasingly sophisticated “patent thickets” around blockbuster drugs. Where compound patents may expire, method-of-treatment and drug-interaction patents can sustain exclusivity barriers well beyond initial patent expiration.

The case also reflects a broader licensing and litigation trend: pharmaceutical innovators are investing heavily in prosecution strategies that generate continuation patent families protecting clinical use cases, creating multiple sequential hurdles for generic entrants. Companies in the endocrinology, oncology, and rare disease therapeutic spaces — where specialized dosing and interaction management is clinically necessary — should anticipate similar enforcement patterns.

For in-house IP teams at pharmaceutical companies, this case reinforces the strategic value of continuation prosecution programs and thorough lifecycle management of pharmaceutical patent estates.